Obesity,
Год журнала:
2023,
Номер
31(5), С. 1280 - 1289
Опубликована: Март 30, 2023
Abstract
Objective
The
aim
of
this
study
was
to
compare
the
effectiveness
semaglutide
versus
liraglutide
for
treating
post‐metabolic
and
bariatric
surgery
(MBS)
weight
recurrence.
Methods
A
retrospective
analysis
207
adults
with
post‐MBS
recurrence
treated
1.0
mg
weekly
(
n
=
115)
or
3.0
daily
92)
at
an
academic
center
from
January
1,
2015,
through
April
2021,
conducted.
primary
end
point
percentage
body
change
12
months
treatment
regimens
containing
liraglutide.
Results
mean
sample
age
55.2
years;
BMI
40.4
kg/m
2
;
89.9%
were
female;
50%
completed
sleeve
gastrectomy,
29%
Roux‐en‐Y
gastric
bypass,
21%
adjustable
banding.
Least‐squares
−12.92%
−8.77%
in
groups,
respectively
p
<
0.001).
adjusted
odds
ratios
2.34
(95%
CI:
1.28‐4.29)
≥10%
loss
2.55
1.22‐5.36)
≥15%
over
group
group,
respectively.
Weight‐loss
efficacy
(vs.
liraglutide)
did
not
differ
by
subgroups
explored,
including
age,
sex,
MBS
procedure.
Conclusions
These
results
show
that
lead
superior
compared
recurrence,
regardless
procedure
type
magnitude
New England Journal of Medicine,
Год журнала:
2022,
Номер
387(3), С. 205 - 216
Опубликована: Июнь 4, 2022
Obesity
is
a
chronic
disease
that
results
in
substantial
global
morbidity
and
mortality.
The
efficacy
safety
of
tirzepatide,
novel
glucose-dependent
insulinotropic
polypeptide
glucagon-like
peptide-1
receptor
agonist,
people
with
obesity
are
not
known.
New England Journal of Medicine,
Год журнала:
2023,
Номер
389(6), С. 514 - 526
Опубликована: Июнь 26, 2023
Retatrutide
(LY3437943)
is
an
agonist
of
the
glucose-dependent
insulinotropic
polypeptide,
glucagon-like
peptide
1,
and
glucagon
receptors.
Its
dose-response
relationships
with
respect
to
side
effects,
safety,
efficacy
for
treatment
obesity
are
not
known.We
conducted
a
phase
2,
double-blind,
randomized,
placebo-controlled
trial
involving
adults
who
had
body-mass
index
(BMI,
weight
in
kilograms
divided
by
square
height
meters)
30
or
higher
BMI
27
less
than
plus
at
least
one
weight-related
condition.
Participants
were
randomly
assigned
2:1:1:1:1:2:2
ratio
receive
subcutaneous
retatrutide
(1
mg,
4
mg
[initial
dose,
2
mg],
8
12
mg])
placebo
once
weekly
48
weeks.
The
primary
end
point
was
percentage
change
body
from
baseline
24
Secondary
points
included
weeks
reduction
5%
more,
10%
15%
more.
Safety
also
assessed.We
enrolled
338
adults,
51.8%
whom
men.
least-squares
mean
groups
-7.2%
1-mg
group,
-12.9%
combined
4-mg
-17.3%
8-mg
-17.5%
12-mg
as
compared
-1.6%
group.
At
weeks,
-8.7%
-17.1%
-22.8%
-24.2%
-2.1%
more
occurred
92%,
75%,
60%,
respectively,
participants
received
retatrutide;
100%,
91%,
75%
those
mg;
93%,
83%
27%,
9%,
2%
placebo.
most
common
adverse
events
gastrointestinal;
these
dose-related,
mostly
mild
moderate
severity,
partially
mitigated
lower
starting
dose
(2
vs.
mg).
Dose-dependent
increases
heart
rate
peaked
declined
thereafter.In
obesity,
resulted
substantial
reductions
weight.
(Funded
Eli
Lilly;
ClinicalTrials.gov
number,
NCT04881760.).
JAMA Surgery,
Год журнала:
2023,
Номер
158(4), С. 410 - 410
Опубликована: Фев. 15, 2023
Hepatocellular
carcinoma
(HCC)
is
the
sixth
most
common
malignancy
and
fourth
leading
cause
of
cancer-related
death
worldwide.
Recent
advances
in
systemic
locoregional
therapies
have
led
to
changes
many
guidelines
regarding
therapy,
as
well
possibility
downstage
patients
undergo
resection.
This
review
examines
surgical
medical
relative
multidisciplinary
treatment
strategies
for
HCC.HCC
a
major
health
problem
The
obesity
epidemic
has
made
nonalcoholic
fatty
liver
disease
risk
factor
development
HCC.
Multiple
societies,
such
American
Association
Study
Liver
Diseases,
European
Liver,
Asian
Pacific
National
Comprehensive
Cancer
Network,
provide
screening
at-risk
patients,
define
staging
systems
guide
optimal
strategies.
Barcelona
Clinic
system
widely
accepted
recently
undergone
updates
with
introduction
new
stage
migration.The
HCC
should
involve
approach
collaboration
among
surgeons,
oncologists,
radiation
interventional
radiologists
care.
Treatment
paradigms
must
consider
both
tumor
patient-related
factors
extent
disease,
which
main
driver
morbidity
mortality.
advent
more
effective
prolonged
survival
advanced
allowed
some
intervention
who
would
otherwise
considered
unresectable.
